Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Cambrex (CBM)
The company has Return on Asset of 8.76 % which means that on every $100 spent on assets, it made $8.76 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 16.0 %, implying that it generated $16.0 on every 100 dollars invested. Cambrex's management efficiency ratios could be used to measure how well Cambrex manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a total capitalization of 2.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cambrex's market, we take the total number of its shares issued and multiply it by Cambrex's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Fennec Pharmaceuticals (FENC)
The company has return on total asset (ROA) of (0.2967) % which means that it has lost $0.2967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.48, whereas Return On Tangible Assets are forecasted to decline to (0.64). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Current Asset Value is expected to grow to about 15.6 M, whereas Total Assets are forecasted to decline to about 16.1 M. The entity currently falls under 'Small-Cap' category with a current market capitalization of 254.2 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fennec Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Fennec Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
31.06 Million
At present, Fennec Pharmaceuticals' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Eagle Pharmaceuticals (EGRX)
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eagle Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.17 in 2024, whereas Return On Equity is likely to drop 0.14 in 2024. At this time, Eagle Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 262.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 8.2 M in 2024. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 58.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eagle Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eagle Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Eagle Pharmaceuticals shows a prevailing Real Value of $7.71 per share. The current price of the firm is $4.77. Our model computes the value of Eagle Pharmaceuticals from reviewing the firm fundamentals such as Profit Margin of 0.05 %, shares outstanding of 12.96 M, and Current Valuation of 116.19 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Cambrex (CBM)
The company has Return on Asset of 8.76 % which means that on every $100 spent on assets, it made $8.76 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 16.0 %, implying that it generated $16.0 on every 100 dollars invested. Cambrex's management efficiency ratios could be used to measure how well Cambrex manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a total capitalization of 2.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cambrex's market, we take the total number of its shares issued and multiply it by Cambrex's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Fennec Pharmaceuticals (FENC)
The company has return on total asset (ROA) of (0.2967) % which means that it has lost $0.2967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.48, whereas Return On Tangible Assets are forecasted to decline to (0.64). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Current Asset Value is expected to grow to about 15.6 M, whereas Total Assets are forecasted to decline to about 16.1 M. The entity currently falls under 'Small-Cap' category with a current market capitalization of 254.2 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fennec Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Fennec Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
31.06 Million
At present, Fennec Pharmaceuticals' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Eagle Pharmaceuticals (EGRX)
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eagle Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.17 in 2024, whereas Return On Equity is likely to drop 0.14 in 2024. At this time, Eagle Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 262.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 8.2 M in 2024. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 58.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eagle Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eagle Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Eagle Pharmaceuticals shows a prevailing Real Value of $7.71 per share. The current price of the firm is $4.77. Our model computes the value of Eagle Pharmaceuticals from reviewing the firm fundamentals such as Profit Margin of 0.05 %, shares outstanding of 12.96 M, and Current Valuation of 116.19 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Commodity Channel Now
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
